/

Supernus Pharmaceuticals, Inc.

SUPN US

SUPN USSupernus Pharmaceuticals, Inc.

United States Composite

30.27

USD

+0.19

(+0.63%)

0.02EPS Dil.

1,254.40P/E

1.66BMarket Cap

Next Earnings

May 7

Held by Insiders

5.12%

Held by Institutions

107.87%

Short % of Float

8.05%

YTD Yield

-20.18%

3Y Yield

-4.22%

5Y Yield

-21.36%

Capital Structure

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

ST Debt

LT Borrowings

- -

LT Finance Leases

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

Market Capitalization

1,641

1,506

1,584

Working Capital

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

Total Current Assets

424

449

493

Cash, Cash Equivalents & STI

152

200

255

Accounts Receivable, Net

137

142

144

Inventories

Total Current Liabilities

253

288

290

Payables & Accruals

208

213

205

ST Debt

Deferred Revenue

- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

90.13%

9.22%

-8.85%

Net Income, GAAP

34.08%

-25.47%

-98.36%

Free Cash Flow

0.77%

-2.58%

-4.31%

Total Cash Common Dividend

- -

Total Equity

44.45%

15.75%

4.06%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

131

141

148

159

580

2022

153

170

177

167

667

2023

154

136

154

164

608

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

0.11

0.45

0.41

0.05

1.01

2022

0.48

0.15

0.03

0.47

1.13

2023

0.31

-0.02

-0.29

0.02

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Company Description

CEO: Mr. Jack A. Khattar
Full Time Employees: 652
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Address: 9715 Key West Avenue Rockville MD United States 20850
IPO Date: May 1, 2012
Website: www.supernus.com
Business: Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

Company News

Yahoo
8 days ago
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
Yahoo
25 days ago
Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease
Reuters
25 days ago
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease
Yahoo
25 days ago
Supernus Provides Regulatory Update for SPN-830
Yahoo
2 months ago
Supernus to Participate in Two Upcoming Investor Conferences

Company Description

CEO: Mr. Jack A. Khattar
Full Time Employees: 652
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Address: 9715 Key West Avenue Rockville MD United States 20850
IPO Date: May 1, 2012
Website: www.supernus.com
Business: Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.